コルキシンと心血管疾患の予防
Lars G Hemkens1, Hannah Ewald1, Matthias Briel2
1Basel Institute for Clinical Epidemiology and Biostatistics, University Hospital Basel, Basel, Switzerland.
JAMA
|September 14, 2016
まとめ
継続的な長期のコルキシン治療は,心筋梗塞のリスクを軽減するが,胃腸の有害事象を増加させる. この発見は,コルキシンを理解するために極めて重要です.
科学分野:
- 心臓病科
- 薬理学について
- 臨床医学
背景:
- コルキシンは抗炎症剤です
- コルヒシンの長期使用は,心血管上の利点について調査されています.
- 安全性を理解することが不可欠です.
研究 の 目的:
- 継続的な長期コルキシン治療と全因死亡率との関連性を評価する.
- 長期にわたるコルキシンによる心筋梗塞率への影響を評価する.
- 長期にわたるコルキシン療法に関連した有害事象の発生率を決定する.
主な方法:
- 観察試験のデザイン
- コルキシン治療期間に関する患者データ分析
- 治療グループ間の死亡率と心筋梗塞率の比較
- 有害事象の報告の評価
主要な成果:
- 継続的な長期のコルキシン治療は,心筋梗塞率の低下と関連している可能性があります.
- コルキシンを長期にわたって使用すると,胃腸の有害事象のリスクが増加することが観察されました.
- あらゆる原因による死亡率との関連は,さらなる調査が必要である.
結論:
- 長期にわたるコルキシン治療は,特に心筋梗塞を減らすことで,心血管の保護を提供することができる.
- 臨床医は,長期にわたってコルキシンを服用している患者の胃腸内部の副作用をモニターし,管理する必要があります.
- リスク・ベネフィットの評価は 個々の患者の管理に不可欠です
関連する概念動画
Drugs that Destabilize Microtubules
4.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K
Coronary Artery Disease IV: Preventive Measures
794
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
794
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.5K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Coronary Artery Disease V: Interprofessional Care
359
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
359
Atherosclerosis III: Management
558
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
558
Peripheral Artery Disease III: Interprofessional Care
494
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
494

